What’s New on AVAC.org

AVAC.org has a host of new resources providing concise updates, informed perspective and handy tools. Take a look at the highlights below and get up to speed on a range of strategic issues.

New Resources

  • AVAC, in partnership with the Clinton Health Access Initiative (CHAI), is taking on new work focused on supporting innovation in the prevention “market”—including the programs that deliver new products and the pipeline of products in trials. This two-page intro to the “HIV Prevention Market Manager” gives an overview of this new body of work.
  • To get a flavor of the work the Prevention Market Manager team is focused on, check out this new resource: End-User Research Landscape Mapping and Findings. The term “end user” is used by people who work on developing and marketing products. It refers to the individual who’s ultimately going to make the decision to seek out and use a given product or intervention. This resource gives a sense of the range of efforts trying to understand what is and isn’t known about one key set of “end users” for new prevention options—adolescent girls and young women in sub-Saharan Africa.

From the Infographics Gallery

  • Introduction to Long-Acting Injectables is an updated graphic to guide you through the basics of antiretrovirals that are being developed as long-acting injectables for both treatment and prevention.

Strong Voices in P-Values

  • Progress and justice for women and girls has come under attack by the new US administration via the reinstatement and proposed expansion of the Global Gag Rule. In Standing Together Against the Global Gag Rule the AVAC team reaffirms its commitment to the fight for bodily autonomy, for justice, for choice and voice for women and girls.
  • In New and Touted HIV bNAb: Big deal or news blip?, veteran science writer and HIV journalist Mark Mascolini delves into the nuances of vaccine research using broadly neutralizing antibodies. You will learn more than just what these are; Mascolini looks at the big promises and the small print.
  • Lindsay Roth, a long-time organizer and advocate for sex workers’ rights, gives any lay reader on the subject of sex work an opportunity to gain a deeper understanding of the issues at stake in Getting Set to Defend and Advance Sex Workers’ Rights in 2017 and Beyond. Roth’s reporting shows how HIV prevention, human rights and economic justice can only succeed together.

Standing Together Against the Global Gag Rule

Wherever you live in the world, you know this to be true: there can be no progress, no justice and no hope for an end to AIDS without progress and justice for girls and women. And this holds true for all people and all “key populations” who are overburdened by the epidemic and underserved by the response, including LGBT individuals, people who use drugs, and those who are incarcerated.

Today we are writing about women. We are writing as the AVAC team to share with our allies, of all genders, that we will not cease fighting for bodily autonomy, for justice, for choice and voice for women and girls.

We are writing this now because progress and justice for women and girls came under attack this week by the new US administration via the reinstatement and proposed expansion of the Global Gag Rule, also known as the Mexico City policy.

The proposed expansion of the Gag Rule now applies to all US global health funding. This has not been enacted yet. Yet. There are many questions about how the expansion might work. We are working to find answers and are tracking the issue closely, along with a growing coalition of partners who recently issued a joint statement. We will be posting a more detailed update and set of resources on <AVAC.org in the coming week.

First created under US President Ronald Reagan, and subsequently rescinded by every Democratic president and reinstated by every Republican president since then, the Global Gag Rule has historically prohibited foreign NGOs receiving US foreign assistance for family planning from talking about, providing, referring or advocating for the legalization of abortion.

This past version of the Gag Rule affected roughly seven percent of US foreign health dollars. And even then it had a destructive impact on women’s bodies and lives. Clinics that provide comprehensive sexual and reproductive health services lost funding. They closed. A study in South Africa documented the impact: Without access to contraception, rates of unintended pregnancy and unsafe abortion went up. The Kaiser Family Foundation has produced a great overview of the policy’s history and how it has been applied in the past, and they plan to update it as more details become available.

In the meantime, we stand together. We situate women and girls’ rights in the broader context of social, economic and health justice. We recognize and stand with the many groups coming under attack from this week’s executive orders. We will stand strong and we will fight harder, smarter and without fear because we know that all of our lives depend on it.

Px Wire’s Take on 2017: #Onwards #UntilTheEpidemicIsOver

2017 promises to be a year of big changes, but how the political winds will touch the field of HIV is still unknown. Amidst the uncertainty, long hard work advancing HIV prevention is pushing frontiers all over the world from the lab to the clinic to the household medicine cabinet.

This issue of Px Wire, AVAC’s quarterly update on HIV prevention research, looks ahead at a host of issues we are watching in 2017. Are we confronting “Fast Track” goals with the sober analysis they demand? Will oral PrEP guidelines translate into programs and will programs meet people’s needs? What progress can we expect from studies on the dapivirine vaginal ring, various vaccine candidates or on broadly neutralizing antibodies, which are garnering so much press attention of late? Will global leaders embrace policies that ensure data gaps on key populations will finally be filled?

Check out AVAC’s round-up of these and other questions that we think will define the state of HIV prevention in 2017. And this issue’s centerspread extends the story beyond 2017 with an infographic showing the status of large-scale prevention trials through 2020.

New and Touted HIV bNAb: Big deal or news blip?

Fervid research has uncovered dozens of antibodies that shield cells from HIV. These broadly neutralizing antibodies (bNAbs) protect monkeys from SHIV, the simian-HIV hybrid. Thousand-person human trials are already dripping bNAbs into high-risk men and women to see if they prevent HIV infection. And much work suggests bNAbs hold promise as keys to HIV vaccine design or as immune therapy delivered by passive immunization or viral vectors.

So what inspired the media handstands proclaiming the discovery of yet another bNAb—one explored so far only in lab tests, inflating a bNAb class already studded with candidates that show potential based on their antiviral activity in lab studies? While human trials of bNAbs are underway, this newest next-generation candidate is years away from human trials. So, does the world need even one probably costly, hard-to-administer bNAb when as-needed PrEP taken consistently before and after sex or PrEP plus antiretroviral therapy for HIV-discordant couples virtually eliminate HIV transmission?

It appears so. All the fuss focused on a bNAb tagged N6, isolated from a volunteer whose immune system had 21 years to mold and remodel the antibody into a form that neutralized 98 percent of global HIV strains Mark Connors and colleagues threw at it—the most ever harnessed by a single bNAb. The diverse and exacting studies performed by this team from the National Institute of Allergy and Infectious Diseases (NIAID) and other centers offer tantalizing evidence that N6 is indeed something special.

Previously studied bNAbs, Connors and coauthors note, are either strong (stalling HIV at a relatively low dose) or broad (blocking a high proportion of tested HIV strains). None claims both distinctions—but N6 does. The new bNAb boasts sweeping breadth, thwarting 98 percent of HIV strains tested, compared with 80 percent to 90 percent neutralization with other bNAbs in this class, which targets the CD4 binding site. But the other CD4-homing bNAbs, observe Scripps researchers Devin Sok and Dennis Burton, wield only “modest potency” compared with N6’s robust median 50 percent inhibitory concentration (IC50) of 0.04 µg/mL. A few other bNAbs in different classes flex even more inhibitory muscle than N6 (median IC50 0.003 µg/mL for bNAb PGDM1400) but have narrower breadth than N6 (83 percent of isolates neutralized by PGDM1400).

bNAbs affix themselves to some stretch of the HIV envelope protein that the virus uses to snag CD4 cells. But the gene that encodes the HIV envelope mutates manically to shirk the embrace of antibodies (and vaccines designed to elicit or transport antibodies). At the same time, HIV shrouds its envelope in a sugar coat poorly recognized by antibodies. So a key measure of bNAb prowess is how well it copes with HIV’s shape-shifting mutations. And by this measure, N6 is a star. Only 4 of 181 HIV strains tested (2 percent) proved highly resistant to N6. Among 20 HIV strains resistant to other bNAbs in the same class as N6, the new bNAb neutralized 16 (80 percent).

To learn how N6 dodges HIV’s resistance defenses, Connors and crew performed a series of rigorous structural analyses showing precisely how N6 seizes HIV’s envelope loops. N6 grabs HIV the same way we grab things—with a hand, or at least something that looks like a hand. Connors’s team asks us to visualize N6 and other antibodies in this class as an index finger and thumb that pinch a sugar-coated shape-shifting part of the HIV envelope called the V5 loop. To resist other CD4 binding site antibodies, HIV warps V5 in a way that pushes away these antibodies to prevent them from binding. Crystal structure analysis showed that, compared with the index finger and thumb of VRC01 (the most-studied bNAb in this class), the finger and thumb of N6 are shorter and differ subtly in rotation and tilt. These subtle changes allow N6 to avoid wrinkles in V5 that cause resistance to other bNAbs in the VRC01 class.

Besides clutching V5, bNAbs in this class finger two other HIV envelope regions, the CD4-binding loop and another loop labeled D. The twist and tilt of N6 relative to other bNAbs make it rely less on V5 and more on loop D to grip HIV. Because loop D shifts shape much less than V5, the N6 hand grabs it more reliably and firmly from one HIV strain to the next.

VRC01, the bNAb now in large placebo-controlled trials to prevent HIV infection in men and women, must be dripped into a vein for 30 to 60 minutes every 8 weeks. Because N6 is 5 to 10 times more potent than VRC01, simpler subcutaneous shots may be possible and at longer intervals. Connors and colleagues suggest the durability of N6 may be further tweaked by mutational manipulation. Anything that simplifies delivery of a preventive or therapeutic agent boosts its chances of successful clinical use.

Autoreactivity (sometimes called self-reactivity) occurs when an agent produced by an organism (like humans) works against that organism. Although autoreactivity may be a defining feature of bNAbs, researchers agree that it represents an obstacle to inducing bNAbs and may account for their rarity in people with HIV. Connors and colleagues performed four binding studies indicating minimal autoreactivity with N6, a benefit that bNAb experts Sok and Burton suggest may favor N6 use for prophylaxis or treatment.

To learn how N6 evolved in their volunteer, Connors and coworkers sequenced B-cell antigen receptors at three times—2012, 2014, and 2015. Hints from these studies and from phylogenetic (evolutionary) analyses may give researchers vital clues to targeting diverse HIV strains with vaccines or immunotherapies. Discovering features shared by N6 and other bNAbs could inform the design of better vaccine and immunotherapy candidates.

Together these propitious traits inspired Sok and Burton to proclaim N6 the “best-in-class” among CD4-binding bNAbs. And given the breadth and brawn of N6, it may not be a stretch to call it the best bNAb period. But caution remains the catchword for any agent at this earliest stage of research. So far everything we know about N6 comes from a single, though exhaustive, 14-page paper, plus supplementary online data. From this point agents like N6 typically require further lab work and studies in animals like mice and monkeys before starting small human trials to assess their safety and find the right dose. Only then can researchers test efficacy in bigger human trials. But bNAb development moves fast these days. The much-vaunted VRC01 got discovered in 2010, its first human trial began only 3 years later, and the above-noted phase 2 efficacy trials are recruiting HIV-negative volunteers right now. Connors told P-Values that several pharma and biotech companies are already collaborating with academic partners to develop N6 for potential clinical use.

Will N6 and other bNAbs play a practical role in global HIV control? A lab study testing seven bNAbs found that the CD4-focused antibody NIH45-46W neutralized 91 percent of 45 global HIV strains. Adding PGT128, a bNAb directed at the V3 loop of HIV’s envelope, crippled 96 percent of tested HIV strains. Supplementing that two-pronged attack with PGT121, another V3 loop grabber, neutralized all HIV strains tested. Perhaps N6 combined with just one more bNAb would protect CD4 cells from all HIV-1 strains.

But right now that approach would prove impractical as a vaccination strategy because large and costly vats of bNAbs would have to be brewed, delivered to big target populations, and injected (as things stand now) every few months. A phase 2 trial of PrEP with cabotegravir, the long-acting integrase inhibitor, is testing intramuscular shots given every 4 or 8 weeks. A PrEP bNAb duo that works when injected at longer intervals would hold a clear convenience advantage over cabotegravir, but potential costs remain unknown, and we have already ventured far into the realm of speculation.

Accepting Applications for the GPP Online Training Course!

AVAC is pleased to announce the fifth offering of its global Good Participatory Practice Online Training Course!

With biomedical research moving forward at a thrilling pace, getting stakeholders involved in clinical trial conduct has never been more important. As of 2017, clinical trials are underway globally around a range of HIV prevention options—long-acting injectables and next-generation PrEP, antibody-mediated prevention, and implementation studies of the dapivirine ring—to name a few. Global rollout of oral Truvada as PrEP is shifting the field’s thinking about clinical trial design. Other advances are also grabbing headlines. Ebola research has led to a safe and effective vaccine, and research continues. New trials are on the horizon for tuberculosis drugs and vaccines.

The Good Participatory Practice (GPP) Guidelines provide a framework for engaging a broad range of stakeholders throughout the clinical trial process, increasing their understanding, commitment and participation in biomedical HIV prevention research. Through interactive modules, online forums that allow for peer-to-peer interaction, webinars and practical assignments—all facilitated by experts in GPP—the course deepens participant capacity to effectively apply GPP in their own contexts.

The course offers two tracks:

Track A is designed for research implementers, or individuals directly responsible for GPP or community engagement at a trial site. All learners who complete the requirements for Track A will receive a GPP Implementer Certificate.

Track B is designed for stakeholders not directly responsible for GPP implementation but interested in understanding GPP concepts and applications, e.g., research coordinators, civil society advocates and regulators. All learners who complete Track B requirements will receive a GPP Course Completion Certificate.

What Former Participants are Saying

To date, 100 percent of previous course participants rank the course as “excellent” or “very good” overall and the majority would recommend it to a colleague. Learners report they consider the interactive modules and facilitator feedback highly valuable. They also tell us the course gave them the tools and confidence to implement GPP. To learn more about the course overall, please click here.

“Taking this course was the best investment of my time in all of 2016. I had a fundamental and intuitive understanding of the principles on which GPP is based, but now I have a structured framework and practical tools for helping to envision and implement the next generation of research advocacy.” –Mark Hubbard, Education Liaison, Tennessee Association of People with AIDS

This course offering will run from 23 January through 28 April 2017. Download the application and submit it to [email protected] by 18 January 2017. For more information please contact Jessica Salzwedel ([email protected]) or Stacey Hannah ([email protected]).

Celebrating a New Class of Stakeholder Engagement Experts

AVAC is happy to announce that another class has graduated from the GPP Online Training Course. GPP, or the Good Participatory Practice Guidelines, provide systematic guidance on effective engagement with stakeholders in the design and conduct of biomedical HIV prevention trials.

Two years ago, the first learners of the GPP Online Training Course completed the 12-week program. The online course is a mixed-method approach designed to strengthen the practice of individuals responsible for stakeholder engagement in research. Using an intensive GPP workplan development approach, webinars, and interactive modules with expert facilitators, the course has amplified the benefits of GPP to an increasing number of researchers, advocates and funders.

To date, 120 participants from 16 countries in Africa, Asia, North and South America, and Europe have received GPP certification through the course. The course’s reach has expanded beyond HIV prevention research to additional fields such as TB drug and vaccine development, diabetes, and emerging pathogens like Ebola. While the primary audience for the course remains individuals responsible for planning and implementing community and stakeholder engagement plans at trial sites, we’re experiencing a growing scope of course participants. For instance, civil society representatives have enrolled to build PrEP advocacy plans in their settings. Trial sponsors, including the pharmaceutical industry, also have a growing interest in taking the course to help develop their own models of GPP implementation.

In addition to the benefit of developing a tailored GPP workplan as a result of the course, learners consistently ascribe great value in learning from their peers in the multi-faceted and diverse course cohorts. Once complete, AVAC helps learners stay connected through the Stakeholder Engagement Community of Practice.

As we move into 2017, AVAC hopes to grow the online course to even higher standards and wider audiences! The next course will begin January 2017. To find out more, including how to apply, please email [email protected].

HIV prevention research is going strong, generating new insights and refining the scientific foundations for defeating the virus. It is both an energized and complicated moment in the field, and stakeholder engagement is key to our collective success. AVAC is proud to acknowledge the accomplishments of all the learners who have become certified in GPP over the past two years!

One Thing We Don’t Want to Forget About 2016: AVAC at year’s end

2016 is fast winding down and for many people the thought is: this year can’t be over quickly enough. It’s been a wild one. Human rights and health care seem more imperiled than ever as a result of political changes in many parts of the world, including here in the US where the core AVAC team is located.

But there’s one thing about 2016 that AVAC and our allies can’t and won’t say goodbye to at midnight on December 31—2016 was the year that the world embraced a comprehensive view of HIV prevention. It was the year that many different stakeholders embraced the reality that the end of epidemic levels of HIV depends on scaling up treatment for people living with HIV and prevention for HIV-negative people.

This was an essential breakthrough that really began, at the global level, with the UNAIDS Prevention Gap report released in advance of the International AIDS Conference in Durban; the special prevention issue of Lancet HIV launched at Durban; and continued with thematic activities and publications focused on the World AIDS Day theme, “Hands Up for HIV Prevention”.

After several years of rhetoric suggesting that the epidemic could be turned around solely by scaling up antiretrovirals for people living with HIV, this broad focus was a refreshing dose of reality.

Beginning to end the HIV epidemic is well within our reach, and it is heavily dependent on providing every person living with HIV antiretrovirals when he or she wants them, in programs that support choice and adherence and lead to durable virologic suppression.

In 2016, the conversation changed. Countries, funders and civil society are increasingly in agreement: Real progress also depends on scaling up voluntary medical male circumcision; oral PrEP for people and places with high incidence; harm reduction programs for the world’s exploding epidemics driven by drug use; comprehensive structural, social and biomedical offerings for all populations at risk; male and female condoms; and sustained commitments to R&D for vaccines, microbicides and PrEP—and much more.

We’re as ready as anyone to shut the book on the worst moments of 2016. But 2016 did give us a gift that we’re taking with us—printing it on a banner, a placard, a card to place above our desks: Prevention matters, progress is possible, people working together for their rights and lives will triumph over time.

Put this in your pocket: AVAC’s wallet-sized holiday wish.

On behalf of the whole AVAC team, warm wishes for joyful, restful restorative holidays and a peaceful New Year.

ROAR on Human Rights Day

Saturday, December 10 was Human Rights Day—the annual commemoration of the UN adoption, in 1948, of the Universal Declaration of Human Rights. As frequent readers of this blog know, AVAC isn’t always convinced that “days” for topics or issues can change the world. But we know to our core that human rights—every day—are essential for progress in HIV and every other health issue.

We live and breathe this commitment in all of our programs and projects. And in this update, we highlight some of the work that is happening via our PxROAR program (Prevention Research, Outreach, Advocacy and Representation)—one of the ways that advocates will be fighting for fundamental rights in the months and year to come.

About PxROAR

AVAC’s PxROAR program is a collaborative space for learning and action, focused on frontline advocates. We share information and ideas on HIV prevention research and implementation advocacy through mentorship, peer support, networking opportunities and technical and financial assistance.

PxROAR US in Action: A focus on sex workers’ rights

The original PxROAR cadre, our US allies focus on the range of issues driving HIV and health disparities in America. We come from across the country and focus on issues of racial justice, LGBT rights, women’s sexual and reproductive health and the intersectionality of agendas. For Human Rights Day, ROARer Lindsay Roth provided a rich look at work on sex workers’ rights in action. Lindsay organizes with the Sex Workers Outreach Project-USA, a collective of sex workers and allies committed to ending stigma and violence towards those in the sex trade. Click here to read her blog.

PxROAR Europe

The PxROAR Europe cadre seeks to contribute to European advocacy for research, development and implementation of new HIV preventions, including AIDS vaccines, microbicides, pre-exposure prophylaxis (PrEP) and treatment as prevention. Another focus for the group is tracking EMA licensing processes and advocating for funding for European-based research through the EU’s Financial Framework 2014-2020 and Horizon 2020. ROAR member Nicholas Feustel was recently recognized as the “Father of PrEP activism” in Germany. Click here to meet Nicholas and the other members.

PxROAR Africa: Frontline advocates working to bridge HIV prevention and human rights

Launched in 2016, PxROAR Africa is the newest cadre in the program. PxROAR Africa is focused on supporting work at the intersection of human rights and HIV prevention. Members represent and work with LGBTQI individuals, sex workers and other criminalized and marginalized populations. Through dialogues, shared learning and strategic action, we seek to advance the human right to health, including comprehensive HIV prevention treatment and care. ROAR Africa is co-led by AVAC’s Cindra Feuer and Micheal Ighodaro—whose recent AVAC blog post on sustaining energy in the fight for human rights for LGBT Africans is a must-read. Click here to read the bios of PxROAR Africa members.

PrEP Won’t Protect if it’s Priced Out of Reach

Kenneth is a 2015 AVAC Advocacy Fellow, hosted by HEPS-Uganda. He works with both grassroots communities and national level stakeholders in promoting health and the rights of people living with HIV in Uganda by advocating for consumer friendly policies. He’s currently the head of HEPS-Uganda’s advocacy program, and coordinates the Uganda Coalition for Access to Essential Medicines.

The cost of providing new tools for preventing HIV infections like oral PrEP is concerning. I hear cries about the sky-high prices of these new prevention options all the time. Unfortunately, after the lament, there’s little conversation about reducing these high costs and enabling access. Access is defined by 4 A’s: Affordability, Acceptability, Accessibility and Availability. Lose any one of them and you lose access – and impact – altogether. For anything and everything you ever wanted to know about PrEP, including information about costs as it becomes available, checkout PrEPWatch.org.

Globally, we have 37 million people living with HIV, but only 50 percent of these are enrolled on treatment. That’s despite the landmark study, HPTN 052, that showed early initiation of antiretroviral treatment in people living with HIV with a CD4 count between 350 and 550, not only improved their health but also reduced HIV transmission to HIV-negative partners by 96 percent.

There is a lot of public taxpayer’s money invested in research and development of new tools for preventing, and managing HIV. No doubt, a lot of innovation and brain power goes into the development of these products and I salute that work. But let’s not forget the ultimate goal of an AIDS-free generation. This can only happen if people, irrespective of their location, gender, race, sexual and political orientation, have access to affordable commodities.

The irony is once these products are out, few can afford them.

The latest prevention option, oral PrEP, has been adopted in guidelines, or is in the process of being adopted, by several countries, both middle and low income, as a prevention option for people at substantial risk HIV infection. However, there are already concerns that the cost of PrEP may be a barrier to access, and that’s partly the reason officials are dragging their feet as they consider adding it to their package of prevention.

Pricing PrEP is still underway, but looking at cost for the delivery of antiretrovirals for treatment may give us an idea. A July 2016 analysis of three ART delivery models in Uganda, published in the Journal of the International AIDS Society, showed that it costs $257 (facility-based model), $332 (a combination of community distribution and facility-based model) and $404 (community distribution model) to deliver ART annually per person. Like ART, the expectation is that most people taking PrEP will receive it for free, and if PrEP delivery costs about the same as ART delivery, this could be a big barrier to its access, especially for low income countries and populations at risk. Someone, somewhere, will have to pay, and $257 to $404 per person per year is quite a high cost.

As we prepare to deliver PrEP, we need to mirror the solidarity and teamwork exhibited when these products were developed. A multi-disciplinary collaboration between potential PrEP users, healthcare providers, government and funders should characterize how we make PrEP accessible to everyone who needs it.

In October, I attended the 2016 HIV Research for Prevention (R4P) Conference in Chicago. Being the only conference focused solely on biomedical HIV prevention, I was really looking forward to hearing new ways to address the access issues I highlighted above. Unfortunately, even here there was too little conversation about protecting public health interests over private commercial interests, which hike prices for new HIV prevention tools. I’m excited by the potential of PrEP to drive new infections down, but I worry that if the high cost of its delivery isn’t checked, PrEP may not realize this potential, especially not in the developing countries where it’s needed most.

Getting Set to Defend and Advance Sex Workers’ Rights in 2017 and Beyond

Lindsay Roth, MSSW is a long time community organizer working with people who use drugs and sex workers. Lindsay is now with the Woodhull Freedom Foundation, a Washington-D.C-based NGO that works to affirm sexual freedom as a fundamental human right. She also organizes with the Sex Workers Outreach Project-USA, a collective of sex workers and allies committed to ending stigma and violence towards those in the sex trade.

Everyone’s worried about the dangers that lie ahead. Is there any good news from 2016?

Well, yes. California voters said “No” to Proposition 60 (Prop 60) this past Election Day, a controversial law that, if passed, would regulate the use of condoms in the porn industry. As stakeholders in the fight against HIV, we should celebrate this victory. We recognize the effort behind this proposed law is but one instance in a systemic disenfranchisement of people in the sex trade, both globally and nationally. And all too often, initiatives like this one are backed by NGOs who claim to serve them but actually do more than good.

In the case of Prop 60, the AIDS Healthcare Foundation (AHF), under the leadership of Michael Weinstein, poured millions of dollars into lobbying for the proposed law, which would have undermined health, safety and self-determination of porn performers. And Weinstein has funded other anti-sex initiatives. In 2012, AHF funded the campaign for Measure B, which called for mandated condom use and eye protection (e.g., goggles—yes, goggles) to protect from bodily fluids on set. California’s Prop 60 would have gone further, encouraging costly and invasive lawsuits against anyone financially tied to a porn production if the condom rule was violated. Weinstein’s work is driven by sex-negative values, and a blatant disregard of science, and other NGOs claiming to serve the interests of sex workers are just as suspect.

Instead of legislating, mandating and criminalizing people over condom use, sex workers need strong worker rights. They need respect and they need access to healthcare. Real HIV prevention depends on sex workers being able to access a range of options from PrEP and condoms to testing and treatment. With that access sex workers can fully protect their health and their human rights.

Stigma against sex work is at the heart of anti-sex worker legislation like Prop 60, Measure B and other problematic legislation that not only makes sex work more dangerous, but drives funding and attention from one of the key drivers of the global HIV crisis: economic inequality. Instead, laws like Prop 60 keep coming.

Prop 60 is a variation on an old theme. It basically expanded on Measure B for all porn production in California, which was voted down by Occupational Safety and Health Standards Board after protests by adult film performers. Prop 60 went beyond mandatory condoms and eye protection and has a number of statutes that put individuals at risk. The sex worker-led site, Free Speech Coalition, articulates the dangers of Prop 60 in detail.

In short, Prop 60 mandated that condoms are visible in every scene of pornographic films made in California—even homemade movies. It would have given all California citizens the ability to sue anyone who has a “financial interest” in the film if the condom rule is violated. Pro-Prop 60 campaigners said this would have held producers accountable for dangerous working conditions for performers, however activists worried this vague language would make performers, especially independent performers who often are also producers, vulnerable to expensive and invasive lawsuits. Prop 60 would have incentivized lawsuits by allowing civilians to profit from them, and made public the legal names and personal information of porn actors in the process of conducting those suits. Additionally, state employees from the Occupation Safety and Health Administration (OSHA) would be paid to watch porn films and ensure condoms are being used. Beyond continuing an anti-sex, anti-worker campaign, this bill, authored under Weinstein’s direction, included a clause requiring the state of California to hire Weinstein to take over enforcement efforts if he determined state efforts were insufficient.

Regulation of the pornography industry is one issue—what are some others?

Michael Weinstein and AHF are but one example of seemingly infinite attacks on the work, lives and safety of sex workers under the guise of helping them. I confronted this often as the Director of Project SAFE in Philadelphia, a peer-led harm reduction organization that provided direct services to women working in underground economies. We worked with the Coalition of Labor Union Women to fight PA HB262, a bill that would mandate a registry of exotic dancers including their eye color, tattoos, home address and personal history of victimization. The work of Project SAFE and many other sex worker-led organizations remains underfunded, as the struggle for the basic human rights, health and safety of people in the sex trade is so often dominated by a “Rescue Industry” that neither understands nor respects our lives and labor.

The “rescue industry” generates hysteria, pulls money from sex worker advocacy and increases HIV risk

Local Republican leadership worked with the Pennsylvania Family Institute, a Christian organization that fights for “traditional” marriage, to create HB262. They claimed it was an effort to “fight human trafficking” as well as reduce HIV and other health risks for exotic dancers. There is no evidence that registries can accomplish any of these goals. But they do put sex workers at greater risk of experiencing violence and exploitation by exposing personal information of a stigmatized workforce. The publication of sex workers’ personal information has led to stalking and “outing,” such as in Seattle, where exotic dancers brought legal action to stop a local court from releasing information to serial offender, Robert Hill. Porn performers in California worried the same would happen to them.

How do these US issues relate to global developments?

Legislation like this laws described above is typical of a global trend. “Anti-trafficking” organizations pressure governments to pass laws that make sex work more dangerous, often in the name protecting people in the sex trade, including victims of human trafficking. The “rescue industry” includes professionals, policy makers, religious leaders and advocates who seek to abolish the sex industry by regulating or criminalizing it out of existence. Most notoriously, the Somaly Mam Foundation, like AHF, used lies to generate hysteria and significant income for its founder, Somaly Mam. Watch-dog groups and journalists have investigated Somaly Mam for an array of abuses including misidentifying sex workers as victims of trafficking, and receiving big sums from donors while doing very little to empower sex workers to lead free and independent lives.

Indeed, saving sex workers, voluntary or trafficked, has become a cause célèbre. But the “rescue industry” often creates more chaos, suffering and stigma for sex workers. The recent proliferation of anti-sex worker organizations has displaced successful sex worker-led programming and interrupted efforts in HIV treatment and prevention, among other important initiatives. For instance, the Young Women’s Empowerment Project in Chicago, a direct service and anti-violence organization for youth of color with ties to the sex trade, lost critical funding to the misleading “end demand” campaigns. “End-demand” campaigns lobby to increase criminal charges for people accused of patronizing sex workers (catchphrases include “no demand, no supply”. Advocates for sex worker rights oppose this type of legislation.

Researchers at DePaul University in Chicago found that end-demand legislation empowered law enforcement to disproportionately profile and arrest Black and Latino men. They also found transgender women accounted for an alarming 10 percent of all arrests during this campaign, suggesting sex sellers were misidentified as sex buyers. Transgender women had their photos, government names and home addresses published in local newspapers as a part of a “John” shaming campaign. This tactic is humiliating and disruptive to anyone’s life, especially transgender women, who are disproportionately the target of violent crimes.

Certain funding policies from the US President’s Emergency Plan For AIDS Relief (PEPFAR) provide yet another example of anti-sex work policies driving funding away from sex workers’ self-advocacy. Despite being found unconstitutional by the US Supreme Court, the Anti-Prostitution Loyalty Oath, established in 2003, forces global recipients of PEPFAR funding to actively oppose prostitution. Efforts to criminalize sex work contradict recommendations from the World Health Organization, the World Bank, the Lancet, Amnesty International and many others, which call for the decriminalization of sex work as fundamental to the human rights of sex workers and instrumental to decreasing the transmission of HIV.

How can HIV Prevention and Sex Worker advocates work as allies?

Sex workers are stakeholders in the fight to end HIV

There is little data about sex workers and HIV in the United States. Transactional sex continues to be excluded from the National HIV/AIDS Strategy, a point that has been protested by activists, as this lack of visibility implies that sex workers are not considered stakeholders in national efforts to end HIV.

In low- and middle-income countries we have more data: sex workers are at elevated risk. HIV prevalence is estimated to be 12 percent of all sex workers – with variations among countries and regions. In several Sub-Sahara African countries, prevalence is as high as 37 percent. Where rates of HIV among sex workers is especially high, only 60 percent have received an HIV test in the past 12 months. In addition, sex workers report difficulties accessing condoms and lubricant, and report other unmet health needs in over 165 countries as a result of criminal laws and/or stigma against them and their work.

Alongside these figures, let us remember that sex work, like all work, is motivated by economic need. The struggle to make sex work safer should not be about mandatory condoms, registries or client-shaming; rather it should address the unequal distribution of wealth in the United States and globally in which so many individuals, especially women, have limited choices for survival.

Stop the stigma—let’s fix the real problems

Wealth inequality, punitive laws and access to health care are but a few of the issues that influence HIV-exposure and other risks that sex workers face. Efforts to end HIV would be far more effective if sex workers were empowered to keep themselves safe, instead of being criminalized, harassed and further isolated from prevention methods or other health care services.

It seems that just about anyone will be entrusted with the safety of sex workers—except sex workers themselves.

We must stay vigilant about the rights of all people in the sex trade. How are sex workers included or excluded in your work? Learn how to be an ally to sex workers here. Consider including sex worker-led organizations in your holiday giving. Only through solidarity can we neutralize the harm of people like Michael Weinstein—and continue to stand up to those who attack the work and the lives of people in the sex trade.